• Guangdong HEC Pharmaceutical won U.S. FDA marketing clearance for insulin glargine injection Langlara, labeled as interchangeable with Sanofi’s Lantus.
• Lannett holds exclusive U.S. sales rights for insulin glargine, with an initial supply order of at least 18 million units over 18 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangdong HEC Pharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260504-12141669), on May 04, 2026, and is solely responsible for the information contained therein.